Jacobs Levy Equity Management, Inc Ngm Biopharmaceuticals Inc Transaction History

Jacobs Levy Equity Management, Inc

$23.2 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.31 $1,666 - $3,639	-2,778 Reduced 0.5%	555,826 $478,000
Q3 2023 Nov 16, 2023	SELL	$1.05 - $3.37 $21,296 - $68,350	-20,282 Reduced 3.5%	558,604 $597,000
Q2 2023 Aug 14, 2023	SELL	$2.44 - $4.53 $401,021 - $744,519	-164,353 Reduced 22.11%	578,886 $1.5 Million
Q1 2023 May 15, 2023	BUY	$3.72 - $5.4 $260,679 - $378,405	70,075 Added 10.41%	743,239 $3.03 Million
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $2.06 Million - $7.82 Million	604,515 Added 880.59%	673,164 $3.38 Million
Q3 2022 Nov 15, 2022	BUY	$12.59 - $17.67 $864,290 - $1.21 Million	68,649 New	68,649 $898,000
Q2 2022 Aug 15, 2022	SELL	$10.58 - $17.5 $3.72 Million - $6.16 Million	-351,943 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$13.81 - $18.6 $1.06 Million - $1.42 Million	-76,483 Reduced 17.85%	351,943 $5.37 Million
Q4 2021 Feb 14, 2022	SELL	$17.26 - $22.02 $509,515 - $650,030	-29,520 Reduced 6.45%	428,426 $7.59 Million
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $4.13 Million - $5.37 Million	205,123 Added 81.13%	457,946 $9.63 Million
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $336,606 - $671,200	22,351 Added 9.7%	252,823 $4.99 Million
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $306,527 - $391,653	12,266 Added 5.62%	230,472 $6.7 Million
Q4 2020 Feb 16, 2021	SELL	$16.21 - $31.44 $172,215 - $334,018	-10,624 Reduced 4.64%	218,206 $6.61 Million
Q3 2020 Nov 16, 2020	BUY	$15.59 - $19.97 $458,876 - $587,796	29,434 Added 14.76%	228,830 $3.64 Million
Q2 2020 Aug 17, 2020	BUY	$11.97 - $23.47 $735,341 - $1.44 Million	61,432 Added 44.53%	199,396 $3.94 Million
Q1 2020 May 15, 2020	BUY	$10.0 - $19.51 $1.38 Million - $2.69 Million	137,964 New	137,964 $1.7 Million

Others Institutions Holding NGM

# of Institutions

Shares Held

2.6M

Call Options Held

300

Put Options Held

View Full List

About NGM BIOPHARMACEUTICALS INC

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

More about NGM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account